



## CANCER OF UNKNOWN PRIMARY IN THE ERA OF PRECISION MEDICINE

Friday 3 May 2019

The Royal College of Physicians  
London

0830 – 0900	Registration and coffee	
0900- 0905	Welcome	<b>John Symons</b>
0905 – 0920	Opening Remarks	<b>Harpreet Wasan</b>
<i>Session 1 – Current Optimal Tissue Diagnostics for CUP</i>		<i>Chair: Harpreet Wasan</i>
0925 – 0940	State of the art immunohistochemistry for the diagnosis of tissue of origin: Royal College of Pathologists standard	<b>John Schofield</b>
0940 – 0955	Evolving morphomolecular pathology in the diagnosis of tissue of origin	<b>Karin Oien</b>
0955 – 1010	The usefulness and potential of the epigenetic/ methylation assay (EPICUP) for tissue of origin diagnosis	<b>Manel Esteller</b>
1010 – 1030	Progress, accuracy and limitations of available molecular cancer classifier assays for tissue of origin diagnosis: review of various assays	<b>Richard Tothill</b>
1030 -1100	Comprehensive genomic profiling of CUP: therapeutic implications	<b>Prasanth Reddy</b>
1100 – 1130	<b><i>COFFEE</i></b>	
1130 - 1155	<i>Panel discussion with audience questions.</i> Diagnostic and Therapeutic importance of tissue of origin analysis and other biomarkers in CUP. Panellists: <b>Drs Schofield, Oien, Tothill, Esteller, Reddy, Cook</b>	
<i>Session 2</i>		<i>Chair: Penny Schofield</i>
1155 – 1210	Update on UK studies including CUP-ONE, CUPEM & 100k Genomes CUP GeCIP	<b>Harpreet Wasan</b>
1210 – 1225	The SUPER Australian study; selected updates and perceptions of CUP by medical oncologists, a national survey	<b>Penny Schofield</b>

1225-1245	Japanese phase II study of empiric chemotherapy versus site-directed therapy based on a molecular cancer classifier assay; Phase III GEFCAP 104 study; global view/background of CUPISCO study: importance and limitations regarding cup management	<b>Alwin Krämer</b>
1245-1300	'The Agony and the Efficacy': UK Perspective on the CUPISCO Trial	<b>Kai-Keen Shiu</b>
1300 – 1400	<b>LUNCH</b>	
<i>Session 2 continued... Current Clinical and Translational Trials</i>		<i>Chair: Penny Schofield</i>
1400 -1420	US studies: Sarah Cannon retrospective CUP subsets, Phase II molecular classifier based site specific therapy; immune checkpoint blockers and MyPathway; NCI Match; ASCO Tapur	<b>Harpreet Wasan</b> on behalf of <b>Tony Greco</b>
1420 -1440	<i>Discussion panel with audience questions:</i> Panelists: <b>Doctors Wasan, Krämer, Shiu, Cook, Reddy</b>	
<i>Session 3 – Optimal management and focus on the future</i>		<i>Chair: Harpreet Wasan</i>
1445 - 1500	Integration of a molecular cancer classifier and comprehensive molecular profiling in selected patients	<b>Harpreet Wasan</b> on behalf of <b>Tony Greco</b>
1500 – 1520	Review of evolving technologies including liquid biopsies and circulating tumour cells	<b>Natalie Cook</b>
1520 -1540	<b>TEA</b>	
1540 – 1555	Whole genome sequencing and immune profiling	<b>Richard Tohill</b>
1555 – 1610	The Cancer Genome Atlas (TCGA) and the search for a CUP genetic/epigenetic signature	<b>Manel Esteller</b>
1610 - 1710	<u>Debates:</u> (10 minutes per speaker)  <ol style="list-style-type: none"> <li>1. Comprehensive molecular profiling should be the preferred test rather than a molecular cancer site of origin classifier assay For: <b>Prasanth Reddy. Against: Natalie Cook</b></li> <li>2. CUP is a clinico-pathological syndrome of many specific cancer types with occult primaries, which have predictable responses to therapies, once classified. For: <b>Alwin Krämer. Against: Harpreet Wasan</b></li> </ol> <u>Audience and speakers' discussion</u> Topic: <b>Optimal management of CUP and future research priorities</b>	
1710 - 1715	Closing remarks	<b>Harpreet Wasan</b>
1730	Drinks and poster prize award	